Completed
Any project, supported or not by a committee, that has not deposited records to the Records Office.
Microphysiological systems (MPS) are in vitro platforms composed of 3-D constructs (including spheroids, organoids, bioprinted, and tissue/organs-on-chips) of human or animal origin in micro-bioreactors that mimic the biochemical, electrical, mechanical properties of organ or tissue function. MPS are predictive tools enabling more physiologically meaningful pharmacology, toxicology and efficacy assessments in drug development. Workshop will discuss current MPS landscape, particularly in developing animal organs-on-chips and establishment of sustainable animal chip banks for large-scale use. MPS will be explored for a range of animal species/strains, including pathogen-free and gene-edited animals, and for optimizing animal model selection where whole animal models are necessary.
Featured publication
Workshop_in_brief
·2021
Microphysiological systems (MPS) are complex, multi-cellular in vitro systems that commonly include three-dimensional aspects, fluid flow, changing pressure or stretch, and multi-organ interactions. These systems are being developed to better mimic some aspects of specific organ systems or combinati...
View details
Description
The National Academies of Sciences, Engineering, and Medicine will appoint a planning committee to organize and convene a workshop on advances in micro-physiological systems (MPS). The purpose of the workshop is to promote discussion and understanding of progress made toward developing more physiologically realistic organs-on-chips (OOCs), particularly with regard to developing animal OOCs and sustainable animal chip banks. Presentations and discussions may explore the following topics and questions:
· What do emerging MPS or OOC technologies enable researchers to achieve that could not be achieved before these artificial biological platforms were developed? Which applications are currently most robust and reproducible?
· How can emerging OOCs or system biology technologies enable researchers to improve in vitro techniques as an alternative to using animal models?
· What are the current strategic goals to advance or improve upon these technologies, particularly as they pertain to reduction of the use of whole live animal models?
· What are the major technological hurdles or knowledge gaps to overcome in order to realize impacts on drug safety testing?
· What are the challenges and opportunities associated with educating and training traditional research scientists to use OOCs?
· What are the determining factors for translating the technologies used for human OOCs to animal OOCs and for creating sustainable animal chip banks?
The workshop presentations and discussions will be documented in a workshop proceedings authored by rapporteur(s) in accordance with National Academies guidelines.
Collaborators
Sponsors
Department of Veterans Affairs
Environmental Protection Agency
National Center for Advancing Translational Sciences
U.S. Department of Agriculture - Animal and Plant Health Inspection Service
U.S. Food and Drug Administration
Staff
Teresa Sylvina
Lead
Major units and sub-units
Center for Health, People, and Places
Lead
Division on Earth and Life Studies
Lead
Institute for Laboratory Animal Research
Lead
Life Sciences and Biotechnology Program Area
Lead